The "Type 1 Diabetes - Global Drug Forecast and Market Analysis to 2029" report has been added to ResearchAndMarkets.com's offering.
The therapeutic market for T1D within the 8MM will grow from $4.9B in 2019 at a significant compound annual growth rate (CAGR) of 17.2% to $24B by 2029.
In particular, the publisher expects the US market will contribute the most to the T1D market's growth, contributing $4.3B sales in 2019 (87.7% of the T1D market) and $20.3B in 2029 (84.7% of the T1D market).
The launch of the first disease-modifying therapeutics will be the main drivers of growth over the forecast period, with the first preventative therapeutic for T1D, Teplizumab, expected to launch in the US during the forecast period. Other major drivers for the T1D market include the increased T1D diagnosed prevalence, and the uptake of novel ultra-rapid-acting and ultra-long-acting insulin analogs.
Based on the epidemiological analysis by the publisher, the diagnosed prevalent cases of T1D in the 8MM will grow by 17.79% over the next decade, from 3,329,294 prevalent cases in 2019 to 3,921,695 prevalent cases in 2029, at an Annual Growth Rate (AGR) of 1.78% per year in the eight major pharmaceutical markets (8MM) covered in this report, the US, 5EU (France, Germany, Italy, Spain, and UK), Japan and Canada.
The consensus among interviewed physicians regarding the current treatment landscape was that while there are a number of insulin treatment options, there are a significant number of patients that are ineffectively managed, and therefore are considerably high unmet needs within the indication.
Key Opinion Leaders (KOLs) interviewed by the publisher highlighted the lack of a no disease-modifying therapeutic that combats the autoimmune-mediated attack of beta cells in T1D patients. Other major issues include glycemic control, addressing obesity, and overall disease management. Despite a number of drugs currently in development, the publisher's research suggests that the future level of attainment of these unmet needs will be modest, and a relatively high level of opportunity exists for drug developers to enter the T1D market.
The diagnosed prevalence of T1D is expected to increase over the 10-year forecast period due changing population demographics, and an increased understanding of risk factors and environmental factors that may trigger the onset of T1D.
The potential launch of 5 disease-modifying therapeutics will increase the number of patients who, at diagnosis, can prolong their endogenous insulin secretion to improve disease management. These drugs are expected to have a high annual cost of therapy (ACOT), a factor that will contribute to notable profitability.
The increasing trend of device integration into the treatment and management of T1D will impact the therapeutics that find success in the market. The drive toward closed-loops systems, like an artificial pancreas, places a great need for ultra-fast insulins to launch in the market, and prompts more collaboration between across the industry.
Despite the variety of insulins currently available to T1D patients, there is still room for improvement within the treatment space. The most recognizable is the need for novel treatment options for refractory patients.
Key Topics Covered:
1 Type 1 Diabetes: Executive Summary
1.1 The Type 1 Diabetes Market Will Grow to $24B by 2029
1.2 T1D Veteran Players Use Various Strategies to Defend Insulin Franchises from Biosimilar Erosion, While New Players Invest in the Disease-Modifying Space
1.3 Current and Future Therapies Leave Significant Unmet Needs in the Market
1.4 The Rise of Pump Usage and Increased Market Entry of Ultra-Rapid-Acting Insulin Formulations May Improve the T1D Treatment Landscape
1.5 Opportunity Remains for Beta Cell Regenerative Therapies
1.6 What Do Physicians Think?
3 Disease Overview
3.1 Etiology and Pathophysiology
3.1.3 Biomarkers for Monitoring the Islet Autoreactivity of Type 1 Diabetes
4.1 Disease Background
4.2 Risk Factors and Comorbidities
4.3 Global and Historical Trends
4.4 Forecast Methodology
4.5 Epidemiological Forecast for T1D (2019-2029)
4.6.1 Epidemiological Forecast Insight
4.6.2 COVID-19 Impact
4.6.3 Limitations of the Analysis
4.6.4 Strengths of the Analysis
5 Disease Management
5.1 Diagnosis and Treatment Overview
5.2 US Disease Management
5.3 5EU Disease Management
5.4 Japan Disease Management
5.5 Canada Disease Management
5.6 KOL Insights on Disease Management
6 Competitive Assessment
7 Unmet Needs and Opportunity Assessment
7.2 Disease-Modifying Therapies - Preservation of Beta Cells
7.3 Hypoglycemia Avoidance and Managing Glycemic Control
7.4 Obesity, Weight Management, and Control of Associated Metabolic Syndrome
7.5 Improving Compliance and Reducing the Burden of Insulin Therapies
7.6 Type 1 Diabetes Patient Care and Education
8 R&D Strategies
8.2 Clinical Trials Design
9 Pipeline Assessment
10 Pipeline Valuation Analysis
11 Current and Future Players
11.2 Deal-Making Trends
11.3 Sanofi Portfolio Assessment, 2021
11.4 Eli Lilly Portfolio Assessment, 2021
11.5 Novo Nordisk Portfolio Assessment, 2021
11.6 Johnson and Johnson Portfolio Assessment, 2021
11.7 Lexicon Pharmaceuticals Portfolio Assessment, 2021
11.8 AstraZeneca, 2021
11.9 Mannkind Corporation, 2021
11.10 Diasome Pharmaceuticals Portfolio Assessment, 2021
11.11 Adocia Portfolio Assessment, 2021
11.12 Biocon Portfolio Assessment, 2021
11.13 Diamyd Medical Portfolio Assessment, 2021
11.14 Zealand Pharma Portfolio Assessment, 2021
11.15 vTv Therapeutics Portfolio Assessment, 2021
11.16 Provention Bio Portfolio Assessment, 2021
11.17 Dompe Farmaceuti Portfolio Assessment, 2021
11.18 PolTreg Portfolio Assessment, 2021
11.19 CellTrans Portfolio Assessment, 2021
12 Market Outlook
12.1 Global Markets
12.1.2 Drivers and Barriers - Global Issues
For more information about this report visit https://www.researchandmarkets.com/r/g79izq
View source version on businesswire.com: https://www.businesswire.com/news/home/20210419005489/en/
Laura Wood, Senior Press Manager
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900